NIAID CLINICAL SITE MONITORING

国家过敏症和传染病研究所获得性免疫缺陷综合症(DAIDS)支持改进艾滋病毒感染及其并发症的治疗方法，并支持开发艾滋病毒/艾滋病疫苗和其他预防措施。通过赠款和合同，DAIDS赞助第一、第二、第三和第四阶段的临床试验，以评估疗法、疫苗和其他预防方式的安全性和有效性。临床现场监测合同的目的将是继续为NIAID/DAIDS临床试验研究组合提供全面的临床现场和研究监测服务，包括为应对新出现的需求或公共卫生紧急情况可能需要的意外DAIDS临床研究项目提供监测服务。

The National Institute of Allergy and Infectious Diseases, Division of Acquired Immunodeficiency Syndrome (DAIDS) supports the advancement of therapies for HIV infection and its complications, and supports the development of HIV/AIDS vaccines and other prevention measures. Through grants and contracts, DAIDS sponsors Phase I, II, III and IV clinical trials to evaluate the safety and efficacy of therapeutics, vaccines and other preventive modalities. The purpose of the Clinical Site Monitoring contract will be to continue to provide comprehensive clinical site and study monitoring services for the NIAID/DAIDS clinical trial research portfolio, including the delivery of monitoring services for unanticipated DAIDS clinical research projects that may be required in response to emerging needs or public health emergencies.